objeCtives: This study determined if treatment of major cancers in Taiwan is cost-effective compared with other major illnesses. Methods: 395,330 patients with pathologically verified cancer, 125,277 patients with end-stage renal disease (ESRD), and 50,481 under prolonged mechanical ventilations (PMV) during 1998-2007 were included and followed until 2007-10. Survival functions for these patients were extrapolated to lifetime based on a semi-parametric method. A convenience sample of measuring utility value with EQ-5D were conducted for 6,189 cancer patients and 1,401 with other major diseases, which were multiplied with survival functions to estimate quality-adjusted life expectancies. The monthly
health care expenditures were abstracted from the reimbursement database of the NHI (National Health Insurance), multiplied by the corresponding survival probabilities, and summed up for lifetime cost with a 3% annual discount rate. We used 22,344 cancer patients with hospice care as a comparison group to conduct generalized cost-effectiveness analysis and estimate cost-per-QALY (qualityadjusted life year). Results: Care of patients under PMV and ESRD showed 2.6 and 0.94-0.99 GDP (gross domestic product= 18,588 US dollars in 2010) of Taiwan per QALY, respectively. All of the nine different cancers were reimbursed less than 1 GDP per QALY. Lung, esophagus and liver cancer were the highest with 0.37-0.46, 0.20-0.43, and 0.23-0.24, GDP per QALY, respectively. The cumulative incidence rates of cancer show a consistent increase for all cancer except those of the stomach, nasopharynx, and cervix. ConClusions: The treatments of major cancers in Taiwan have been cost-effective, but prevention is still the fundamental solution for a sustainable NHI.
PHS66 WaSte and CoSt MiniMization of alkaline Solution By Standardization ProCeSSeS Control for aMBulatory HeModialySiS: a SiMulation Study
de Moraes Junior CS, Colugnati FAB Federal University of Juiz de Fora, Juiz de Fora, Brazil objeCtives: There are few studies about costs of inputs used in hemodialysis and among these expenditures, the compounds that make up the dialysate are one of the values considered as representative of this therapy. However, there aren't costs studies that guiding solutions. The objective of this article is discuss whether there is wasteful of alkaline solutions in ambulatory hemodialysis and hence the possibility of reduction in cost from the standardization process of establishment of dialysate flow in periods between shifts in hemodialysis outpatients. Methods: Starting from a observational analytic cross-sectional research from a real case study at a hemodyalysis clinic, a study was conducted with simulated twenty case scenarios based on different outpatient profiles that affect the solution flow, havig ten cases established by standardizing processes control on the dialysate flow in recession and other ten without this standartization. The combination of data was performed using as a basis the prices of three suppliers of alkali liquid or powder. Results: It was observed savings among the scenarios with standardized processes ranging between 7.7% and 33.3% in the alkaline solution cost (powder or liquid), by reducing waste. ConClusions: It is possible to restrain the wasteful use of alkaline solutions, both powder and liquid. Consequently, its cost from the patterning on reducing the flow of dialysate during the intervals between shifts observed in the outpatient hemodialysis. However, these results are conditional upon the commitment of health professionals, mainly to supervision exercise and control of activities in quality function deployment.
PHS67

StrategieS and interventionS to reduCe tHe SoCio eConoMiC iMPaCt of anxiety and dePreSSion at tHe WorkPlaCe
Razzouk D 1 , Pinheiro MDA 2 1 Universidade Federal de Sao Paulo, Sao Paulo, Brazil, 2 Fundação Getulio Vargas, Sao Paulo, Brazil intRoduCtion: The presence of mental disorders at workplace has been related with absenteeism and decreasing in work performance and in productivity. There are some effective interventions available that can be implemented to reduce the socio economic impact of mental disorders like anxiety and depression at the workplace. objeCtives: To identify the evidence-based interventions available to prevent and to treat anxiety and depression at the workplace and to explore in what extent these interventions have impact on reducing the socio economic effects of mental disorders. Methods: A search based on depression, anxiety, interventions, prevention, workplace, absenteeism, presenteeism, indirect costs was built in Medline database. Studies were included if they described the intervention and method and their effects on absenteism, presenteeism and costs at workplace. Results: Five main interventions were identified: workplace screening for anxiety and depression disorders and care management: interventions are usually delivered throughout cognitive behavioral therapy (CBT), offered by external psychological service providers; CBT through web-based program: it is offered a web-based program to selected employees. Benefits come out of tackling the disorder and increasing productivity levels due to the reduction of presenteeism; interventions promoting well-being in the workplace: it includes flexible time schedules, career growth opportunities and mental health risk factors recognition training program for managers; financial education: workshop for selected employees to advise them on how to better manage their debts, reducing financial burden and consequently, reducing mental health problems; antidepressant drugs for anxiety and depression: these medicines have a positive impact on the work performance and on the decrease of absenteeism rate. ConClusions: The studies selected demonstrated a clear benefit of five interventions for depression and anxiety at workplace: improvement in employees´ performance, in quality of life, reduction of health services costs, decrease in absenteeism rate, in accidents, in sick leave benefits and in early retirement.
PHS68 effiCienCy of tHe Brazilian SySteM of renal tranSPlantation: an analySiS uSing dea and MalMquiSt index MetHod (2006-2011)
Balbinotto G 1 , Favoretto C 2 , Sampaio L 3 1 Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, 2 Cesumar, Porto Alegre, Brazil, 3 UFRN, Porto Alegre, Brazil objeCtives: The purpose of this article is to analyze the efficiency of the Brazilian States in the public system of kidney transplant, in the years 2006 and 2011; and evaluate the performance of the efficiency of these States throughout this period of time. Thus sought to analyze the behavior of States in this sector, before and after the institutional changes adopted by SUS in October of 2009. Methods: The methodology used was data envelopment analysis (DEA) based on Slack (Slack ($7,530) for Mbagathi and Moi respectively, and the discounted life time effects were to 7.73 years and 6.52 years respectively. ConClusions: ART treatment was the most cost effective treatment method and although patients on treatment follow up in Moi lived longer, Mbagathi Hospital was most cost effective intervention.
PHS63
CoSt-effeCtiveneSS analySiS of a PHarMaCiSt-led intervention on iMProving inHaler adHerenCe in PatientS WitH CHroniC oBStruCtive PulMonary diSeaSe
van Boven JF 1 , Tommelein E 2 , Boussery K 2 , Mehuys E 2 , Vegter S 1 , Brusselle GG 3 , Rutten-van Mölken MPMH 4 , Postma MJ 1 1 University of Groningen, Groningen, The Netherlands, 2 Ghent University, Ghent, Belgium, 3 Ghent University Hospital, Ghent, Belgium, 4 Erasmus University Rotterdam, Rotterdam, The Netherlands objeCtives: The Belgian community pharmacist-led PHARMACOP intervention provided educational inhalation training sessions and motivational interviewing regarding medication use in patients with Chronic Obstructive Pulmonary Disease (COPD). The program significantly improved medication adherence and inhalation techniques compared with usual care. This study aimed to evaluate its costeffectiveness. Methods: An economic analysis was performed from the Belgian health care payer's perspective. A Markov model was constructed in which a cohort of 1,000 patients with COPD receiving the 3-month PHARMACOP-intervention or usual care, was followed. This cohort had a mean age of 70 years, 66% were male, 43% current smokers and patients had a mean Forced Expiratory Volume in 1 second of % predicted of 50. Three types of costs were calculated: intervention costs, medication costs and exacerbation costs. Outcome measures included the number of hospital-treated exacerbations, cost per prevented hospital-treated exacerbation and cost per Quality Adjusted Life-Year (QALY) gained. Follow-up was 1 year in the basecase analysis. Univariate-, probabilistic sensitivity-and scenario analyses (including long-term follow-up) were performed to assess uncertainty. Results:
In the basecase analysis, the average overall costs per patient for the PHARMACOPintervention and usual care were € 2,221 and € 2,448, respectively within the 1-year time horizon. This reflects cost savings of € 227 for the PHARMACOP-intervention. The PHARMACOP-intervention resulted in the prevention of 71 hospital-treated exacerbations (167 for PHARMACOP versus 238 for usual care), i.e. 0.07 (95%CI: 0.04-0.10) incremental hospital-treated exacerbations per patient. In addition, a small (< 0.001 QALYs) increase in QALYs was observed. Results showed robust costsavings in various sensitivity analyses. ConClusions: Optimization of current pharmacotherapy (e.g. close monitoring of inhalation technique and medication adherence) has been shown to be cost-saving and should be considered before adding new therapies.
PHS64
SCreening for aBdoMinal aortiC aneurySM: a CoSt-effeCtiveneSS analySiS
Ingels JB, Ebell MH, Corso PS University of Georgia, Athens, GA, USA objeCtives: The USPSTF currently recommends one-time ultrasound screening for all men at age 65 years (B recommendation), while screening for female eversmokers is a C recommendation due to a perceived small net benefit. Our goal was to assess the cost-effectiveness of a one-time ultrasound screening and follow-up surveillance for abdominal aortic aneurysm (AAA) in men and women who do and do not smoke. Methods: We constructed a Markov model using the best available clinical data following screening at age 65. AAA-specific costs (2012 US dollars) were assessed from a health care system perspective, benefits were QALYs gained, and both costs and benefits were discounted at 3%. To assess the uncertainty around model parameters, we conducted a probabilistic sensitivity analysis. Furthermore, we tested individual parameter and structural uncertainty using analysis of covariance and one-way sensitivity analyses. Results: The ICER for screening female smokers is $24,000 per QALY gained. Other potentially cost-effective options include screening all smokers, $49,000 per QALY gained, and all females and male smokers, $110,000 per QALY gained. Screening all individuals is not likely to be cost-effective with an ICER over $200,000 per QALY gained. The probabilistic sensitivity analysis indicates that at willingness-to-pay thresholds of $50,000 and $100,000 per QALY gained, screening all smokers is a cost-effective option. The discount rate was the only parameter or assumption found to appreciably change the interpretation of the final results with a 0% rate making screening everyone cost-effective and a 10% rate screening no one the only cost-effective option. ConClusions: To date, few women have been included in RCTs, and a trial adequately powered to evaluate the net benefits of screening for AAA in women seems unlikely. Our analysis found that the group with the most favorable ICER was actually female smokers, with screening all smokers also likely to be a cost-effective option.
PHS65 generalized CoSt-effeCtiveneSS analySiS for Care of Major CanCerS and otHer Major illneSSeS in taiWan
objeCtives: Diagnosis and monitoring of lymphoma includes lymph node assessment. This study examined the association of multiple lymph node biopsies and health care resource use among lymphoma patients. Methods: Patients with ≥ 2 claims for Hodgkin lymphoma (HL) or non-Hodgkin's (NHL) lymphoma from 1/1/06-12/31/12 were identified from a large US claims database; the index date was the first lymphoma claim date. Patients were retained if continuously enrolled in the health plan for ≥ 12 months before and after the index date, were not diagnosed with lymphoma during the pre-index period or diagnosed with cancer other than lymphoma. Health care cost and utilization were examined during the 2-year study period. Indication of receipt of biopsy included ≥ 1 claim for a lymph node biopsy (core needle, fine needle, surgical, other), pathology, or tumor excision (bone marrow biopsy not included). Health care cost and utilization was examined among patients with 0 to ≥ 3 biopsies. The cost of claims indicating biopsy was identified for each biopsy type. Results: 20,813 newly diagnosed lymphoma patients met all inclusion criteria. 16,557 (80%) had ≥ 1 claim indicating biopsy, 12,920 (62%) had ≥ 2 and 8,783 (42%) had ≥ 3. The percentage with an inpatient stay and ER visit was greatest among patients with ≥ 3 biopsies (52%, 53%) compared to patients with 2 (33%, 41%), 1 (25%, 34%), or 0 biopsies (26%, 42%). Total health care cost was greatest among patients with ≥ 3 biopsies ($102,465) compared to 2 ($51,565), 1 ($25,614), or 0 biopsies ($15,671). The cost of biopsies ranged from $307 for a fine needle biopsy to $3,296 for a complex surgical biopsy and $12,353 for other biopsies. Biopsies involving the mediastinum cost $10,554 on average. ConClusions: Lymphoma patients incur significant health care cost and utilization. Increasing the efficiency of lymph node diagnosis could avoid the need for repeat biopsies and reduce health care costs.
PHS73
CoStS of Pilot PrograMS in CHiCago-BaSed CenterS for PoPulation HealtH and HealtH diSParitieS: a CaSe for teaM-Care?
Walton S 1 , Johnson TJ 2 , Powell LH 2 , Emery EE 2 , Rothschild SK 2 , Joyce B 3 , Li CC 2 1 University of Illinois at Chicago, Chicago, IL, USA, 2 Rush, Chicago, IL, USA, 3 University of Illinois Chicago, Chicago, IL, USA objeCtives: To measure the costs of two team-care based pilot interventions. These interventions are part of the Chicago-based National Institutes of Health-funded Centers for Population Health and Health Disparities (CPHHD) designed to improve health outcomes in medically underserved communities. Methods: The data come from two Chicago-based CPHHD randomized controlled trials. Use of a virtual team aimed at reducing depressive symptoms in older adults with depression (BRIGHTEN Heart) and cardio-metabolic syndrome and use of a patient navigator to improve diagnostic follow-up of mammography screening for breast cancer. The programs collected detailed data regarding service delivery and resource use. Costs were measured from a provider perspective. Actual time spent with patients was estimated in the navigator program using details on activities performed and previous time study data for those activities in similar programs. Time was converted to costs based on average wages reported by the Bureau of Labor Statistics (BLS) by occupational title. BRIGHTEN Heart involved multiple services along with time and travel cost estimates for each occupation and service. Results: There were 493 patients that received patient navigator services and 16 patients in the virtual team-based BRIGHTEN Heart intervention. The patients were almost all minorities and were below average in terms of income and education. The operating cost of the Navigator program was $14.29 following diagnostic screening. The operating cost for the year of virtual team care in BRIGHTEN Heart was $753.18. ConClusions: Costs are an important consideration for evaluating team-care based interventions to improve patient health in the underserved. The two programs evaluated here offer insight into the relatively low cost of interventions with team-care strategies employing allied health workers. Given the low cost of care, the programs offer promise of being cost effective. Future work will examine these costs in comparison to the effectiveness of the program.
PHS74 treatMent PatternS and HealtH Care reSourCe utilization of PatientS WitH neuroendoCrine tuMorS in tHe united StateS
Chuang CC 1 , Dinet J 2 , Bhurke S 1 , Chen SY 1 , Brulais S 2 , Gabriel S 2 1 Evidera, Lexington, MA, USA, 2 IPSEN Pharma, Boulogne Billancourt, France objeCtives: To examine patient characteristics, treatment patterns, and health care resource utilization of patients with neuroendocrine tumors (NETs) in the US. Methods: Using a US administrative claims database, commercially-insured adults newly diagnosed with carcinoid tumors (ICD-9-CM: 209.xx) or pancreatic islet cell tumors (ICD-9-CM: 157.4 and 211.7) between 07/01/2007 and 12/31/2010 were identified (the date of the first observed diagnosis as the index date). Patients were required to have 6-month pre-index and 12-month post-index continuous enrollment. Descriptive analysis was performed to describe demographic and clinical characteristics, treatment patterns for NETs, and health care resource utilization during the 12-month post-index period. Similar analysis was conducted for Medicare-eligible individuals with the supplemental private insurance. Results: This study included 3,940 commercially-insured individuals (mean age: 52.3 years; 55.4% female) and 1,658 Medicare-eligible individuals (mean age: 74.9 years; 49.0% female) with NETs. In the commercial population, carcinoid syndrome (33.2%), liver metastasis (22.4%), and nausea/vomiting (18.2%) were most common among the comorbidities evaluated. While 19.5% of individuals received surgical therapy and 17.5% received medical therapy (somatostatin analogue treatment) as the firstline treatment, nearly two-thirds received neither of those treatments. During the 12-month post-index period, about half of individuals had inpatient hospitalization and 35.4% had emergency room visits; the mean physician office visit was 19.9. In the Medicare population, carcinoid syndrome (27.4%), liver metastasis (20.7%), and diarrhea (16.1%) were the most prevalent comorbidities. While 13.2% received surgical therapy and 19.8% received medical therapy, over two-thirds received neither. Approximately half of individuals had inpatient hospitalization and 37.3% had emergency room visit during the 12-month post-index period; the mean physician office visit was 26.1. ConClusions: This exploratory study described real world Based Measure-SBM) and Malmquist index with Clearances. The sum of these two items is corresponding to the total expenditure in the sector analysed. Output: the output is defined as the number of renal transplants performed by every Brazilian State. Results: Examining the decomposition of the Malmquist index, has that 18 States increased the index of pure change of efficiency (Pairing) with values greater than 1. According to the results, 21 States have submitted an index less than 1, indicating an offset of the boundary of production to a lower level. The analysis of efficiency of Brazilian States proposed in this study indicates a need for a better allocation and/or application of the resources spent by the SUS in the area of kidney transplants. ConClusions: The results of this survey suggest that the process of kidney transplants has presented an activity with great variability between States. The offer of the kidney organ becomes insufficient in these places to meet the demand, creating queues of waiting for a kidney transplant. The system of kidney transplants in Brazil, in the current period, presents a number of surgeries that are below the population's needs, due mainly to the lack of effective donations of this organ.
PHS69 eConoMiC iMPaCt of PatientS WitH tuBerouS SCleroSiS CoMPlex (tSC) in tHe uk: a retroSPeCtive dataBaSe analySiS in tHe CliniCal PraCtiCe reSearCH datalink (CPrd)
Demuth D 1 , Nasuti P 1 , Lucchese L 1 , Gray L 2 , Pinnegar A 2 , Magestro M 3 1 IMS Health, London, UK, 2 Novartis Pharmaceuticals UK Limited, Frimley, UK, 3 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA objeCtives: TSC is a multi-system genetic disorder that affects up to 8,000 patients in the UK. It is associated with non-malignant lesions throughout the body, neurological manifestations, and impaired cognition. Consequently, the burden on patients, their families, and the health care system is thought to be substantial. This study assesses the real-world economic impact of TSC in the UK. Methods: TSC patients were retrospectively identified between April, 1997 to March, 2012 in CPRD (Read: PK5.00, PK5.12) and linked Hospital Episodes Statistics (HES; ICD-10: Q85.1) databases. Health care encounters in the following settings were analysed: general practitioner (GP), inpatient, emergency room (ER) admissions and outpatient. Analyses were stratified by age at time of occurrence for pediatrics (< 18 years) and adults (≥ 18 years). Results: A total of 341 TSC patients were identified (52% female; median age 14.4 years at first event). The annual rate (mean[SD]) of health care encounters (by person-year) was 13.7(14.3) for paediatrics and 15.6(15.3) for adults. Annual rates (mean[SD]) of paediatric vs. adult encounters by care setting was as follows: GP, 10.1(3.1) vs. 12.9(14.2); inpatient, 1.0(1.6) vs. 0.6(1.0); ER admission, 0.4(0.8) vs. 0.3(0.7); outpatient, 3.9(3.3) vs. 2.8(3.0). Neurological manifestations (primarily epilepsy, including infantile spasms and status eptilepticus) were most common in pediatrics resulting in inpatient and ER admission use in 53% and 62% of patients, respectively. Musculoskeletal manifestations were most common in adults resulting in inpatient and ER use in 31% and 33% of patients, respectively. Mean(SD) number of surgical procedures and tests/patient-year was 0.2(0.4) and 0.3(0.4), respectively. MRI or CT scans were observed in 34% of pediatrics and 26% of adults. ConClusions: Health care resource utilization rates suggest significant economic burden of TSC throughout life. Absence of MRI or CT procedures may signify deviation from recommended monitoring guidelines. Further analyses will quantify the cost impact of TSC on the UK health care system.
PHS71 HigH CoSt PatientS and CoSt PatternS froM PediatriC to adult Care in a MediCaid PoPulation WitH SiCkle Cell diSeaSe
Blinder M 1 , Sasane M 2 , Fortier J 3 , Paley C 2 , Duh MS 4 , Vekeman F 3 1 Washington University in St. Louis, St. Louis, MO, USA, 2 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3 Groupe d'analyse, Ltée, Montréal, QC, Canada, 4 Analysis Group, Inc., Boston, MA, USA objeCtives: The aim of this study was to identify high cost sickle cell disease (SCD) patients (HCSPs) and analyze their cost patterns throughout lifetime and as they transition from pediatric to adult care. Methods: State Medicaid data from 1997 to 2010 were analyzed. Patients with ≥ 2 SCD diagnoses and ≥ 1 blood transfusion were included. HCSPs were defined as the fraction of most expensive patients accounting for 50% of the total yearly costs. Periodic events associated with high costs are likely to be responsible for high total costs. High cost events (HCEs), defined as quarters with costs ≥ $33,095, corresponding to the amount separating the top 5% most expensive quarters observed in the sample, were analyzed. A longitudinal logistic regression model was used to identify factors associated with HCEs. Results: From a cohort of 3,208 eligible SCD patients, 449 (14%) were identified as HCSPs. The average yearly total cost of HCSPs was significantly higher at $108,524/year compared to $17,683/year for other patients. The share of the total yearly costs of HCSPs increased from 34.4% to 46.3% between age groups 11-15 and 16-20, reaching its maximum at 65.2% in the 26-30 age group. The frequency of HCEs increased by 122.6% in the transitioning group from 0.110 HCE/year among patients aged 11-15 to 0.244 HCE/year among patients aged 16-20. Patients were more likely to have a HCE during the post-transition period (adjusted odds ratio [OR]: 1.41, p= .0046) and when experiencing an SCD complication (OR: 3.79, p< .0001). Blood transfusions received during the previous quarter were associated with a lower likelihood of HCEs (OR: 0.87, p= .0080). ConClusions: In this population of Medicaid SCD patients, 14% were responsible for over 50% of total yearly health care costs. Directing appropriate and targeted interventions can help assist providers improve outcomes and lower health care costs in this patient population.
PHS72 tHe CoSt of MultiPle lyMPH node BioPSy ProCedureS to tHe united StateS HealtH Care SySteM aMong PatientS diagnoSed WitH lyMPHoMa: a CoMMerCial HealtH Care dataBaSe analySiS
Chastek B 1 , Byfield S 1 , Bodnar CE 2 1 OptumInsight, Eden Prairie, MN, USA, 2 BresMed, Sheffield, UK
